SCHEDULE: Susquehanna Discloses 6.3% Passive Stake in Nektar
Beneficial Ownership Disclosure
Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC have jointly reported a 6.3% passive beneficial ownership in Nektar Therapeutics common stock.
Summary
- Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC (collectively, 'Reporting Persons') have filed a Schedule 13G, disclosing beneficial ownership of Nektar Therapeutics common stock.
- The Reporting Persons collectively beneficially own 1,235,864 shares of Nektar Therapeutics common stock.
- This aggregate ownership represents 6.3% of Nektar Therapeutics' outstanding common stock.
- The ownership includes options to buy 294,911 shares held by Susquehanna Securities, LLC.
- As of September 30, 2025, Nektar Therapeutics had 19,652,513 shares of common stock outstanding.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Nektar Therapeutics.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that directly impacts the company's operational or financial performance, thus maintaining a neutral sentiment.
Positives
- The disclosure of a significant passive stake by institutional investors like Susquehanna can signal confidence in Nektar Therapeutics' long-term prospects.
- Increased institutional ownership can sometimes lead to greater market liquidity and investor interest in the stock.
Future Outlook
The filing does not provide any forward-looking statements or guidance from Nektar Therapeutics or the Reporting Persons regarding the company's future performance or strategic direction.
Industry Context
This filing reflects a standard institutional investment disclosure, indicating that Susquehanna, a prominent financial services firm, has taken a significant passive stake in Nektar Therapeutics. Such filings are common in the biotechnology sector, where institutional investors often build positions in companies with promising pipelines or market potential.
Stakeholder Impact
- Shareholders: May view the institutional investment as a positive signal, potentially increasing confidence in the company's stock.
- Company Management: Awareness of a significant institutional shareholder may influence strategic decisions, though the filing explicitly states the investment is passive.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement, and the date for which Nektar Therapeutics' shares outstanding were reported. |
| 11/07/2025 | Date Nektar Therapeutics' Quarterly Report on Form 10-Q was filed, indicating shares outstanding. |
| 11/13/2025 | Date the Schedule 13G and Joint Filing Agreement were signed. |
Keywords
Nektar Therapeutics, NKTR, Susquehanna, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.